{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:15:59Z","timestamp":1782166559546,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7182100"],"award-info":[{"award-number":["7182100"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic obstructive pulmonary disease (COPD) patients with different phenotypes show different clinical characteristics. Therefore, we conducted a meta-analysis to explore the clinical characteristics between the non-exacerbator (NE) phenotype and the frequent exacerbator with chronic bronchitis (FE-CB) phenotype among patients with COPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CNKI, Wan fang, Chongqing VIP, China Biology Medicine disc, PubMed, Cochrane Library, and EMBASE databases were searched from the times of their inception to April 30, 2019. All studies that reported the clinical characteristics of the COPD phenotypes and which met the inclusion criteria were included. The quality assessment was analyzed by Cross-Sectional\/Prevalence Study Quality recommendations. The meta-analysis was carried out using RevMan5.3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ten cross-sectional observation studies (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098848) were included. Compared with the NE phenotype, patients with the FE-CB phenotype showed significantly lower forced expiratory volume in 1 s percent predicted (FEV\n                      <jats:sub>1<\/jats:sub>\n                      %pred) (mean difference (MD) -8.50, 95% CI -11.36\u2013-5.65,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u00a0=\u200991%), forced vital capacity percent predicted (FVC%pred) [MD \u2212\u20096.69, 95% confidence interval (CI) -7.73\u2013-5.65,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u00a0=\u20095%], and forced expiratory volume in 1 s\/forced vital capacity (FEV\n                      <jats:sub>1<\/jats:sub>\n                      \/FVC) (MD -3.76, 95% CI -4.58\u2013-2.95,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u00a0=\u20090%); in contrast, Charlson comorbidity index (MD 0.47, 95% CI 0.37\u20130.58,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u00a0=\u20090], COPD assessment test (CAT) score (MD 5.61, 95% CI 4.62\u20136.60,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u00a0=\u200980%), the quantity of cigarettes smoked (pack-years) (MD 3.09, 95% CI 1.60\u20134.58,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u00a0=\u200941%), exacerbations in previous year (2.65, 95% CI 2.32\u20132.97,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u00a0=\u200991%), modified Medical British Research Council (mMRC) score (MD 0.72, 95% CI 0.63\u20130.82,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u00a0=\u200957%), and body mass index (BMI), obstruction, dyspnea, exacerbations (BODEx) (MD 1.78, 95% CI 1.28\u20132.28,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u00a0=\u200991%),\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u00a0=\u200934%) were significantly higher in patients with FE-CB phenotype. No significant between-group difference was observed with respect to BMI (MD-0.14, 95% CI -0.70\u20130.42,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.62,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u00a0=\u200975%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>COPD patients with the FE-CB phenotype had worse pulmonary function and higher CAT score, mMRC scores, frequency of acute exacerbations, and the quantity of cigarettes smoked (pack-years) than those with the NE phenotype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-020-1126-x","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T14:07:04Z","timestamp":1587650824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review"],"prefix":"10.1186","volume":"20","author":[{"given":"Jian-jun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-ri","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-yong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-duo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"issue":"149","key":"1126_CR1","doi-asserted-by":"publisher","first-page":"180022","DOI":"10.1183\/16000617.0022-2018","volume":"27","author":"VK Sidhaye","year":"2018","unstructured":"Sidhaye VK, Nishida K, Martinez FJ. Precision medicine in COPD: where are we and where do we need to go? Eur Respir Rev. 2018;27(149):180022.","journal-title":"Eur Respir Rev"},{"key":"1126_CR2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2147\/COPD.S159915","volume":"13","author":"A Di Stefano","year":"2018","unstructured":"Di Stefano A, Coccini T, Roda E, et al. Blood MCP-1 levels are increased in chronic obstructive pulmonary disease patients with prevalent emphysema. Int J Chronic Obstructive Pulmonary Disease. 2018;13:1691\u2013700.","journal-title":"Int J Chronic Obstructive Pulmonary Disease"},{"issue":"12","key":"1126_CR3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1164\/rccm.201710-2028PP","volume":"197","author":"FJ Martinez","year":"2018","unstructured":"Martinez FJ, Han MK, Allinson JP, et al. At the root: defining and halting progression of early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(12):1540\u201351.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1126_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.arbres.2017.03.018","volume":"53","author":"M Miravitlles","year":"2017","unstructured":"Miravitlles M, Soler-Catalu\u00f1a JJ, Calle M, et al. Spanish guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC)2017.Pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324\u201335.","journal-title":"Arch Bronconeumol"},{"issue":"46","key":"1126_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017996","volume":"98","author":"J-J Wu","year":"2019","unstructured":"Wu J-J, Xu H-R, Zhang Y-X, et al. The characteristics of the frequent Exacerbators with chronic bronchitis phenotype and the asthma-chronic obstructive pulmonary disease overlap syndrome phenotype in chronic obstructive pulmonary disease patients: a meta-analysis and system review. Medicine (Baltimore). 2019;98(46):e17996.","journal-title":"Medicine (Baltimore)"},{"key":"1126_CR6","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.2147\/COPD.S154716","volume":"13","author":"A Kania","year":"2018","unstructured":"Kania A, Krenke R, Kuziemski K, et al. Distribution and characteristics of COPD phenotypes-results from the polish sub-cohort of the POPE study. Int J Chronic Obstructive Pulmonary Disease. 2018;13:1613\u201321.","journal-title":"Int J Chronic Obstructive Pulmonary Disease"},{"issue":"11\u201312","key":"1126_CR7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s00508-018-1347-7","volume":"130","author":"G Reiger","year":"2018","unstructured":"Reiger G, Zwick R, Lamprecht B, et al. Phenotypes of COPD in an Austrian population: national data from the POPE study. Wien Klin Wochenschr. 2018;130(11\u201312):382\u20139.","journal-title":"Wien Klin Wochenschr"},{"key":"1126_CR8","first-page":"1115","volume":"13","author":"A-N Bernardino","year":"2018","unstructured":"Bernardino A-N, Antonio TJ, Antonio RJ, et al. Geographic variations of the prevalence and distribution of COPD phenotypes in Spain: \u201cthe ESPIRAL-ES study\u201d. Oxidative Med Cell Longev. 2018;13:1115\u201324.","journal-title":"Oxidative Med Cell Longev"},{"key":"1126_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.niox.2016.02.003","volume":"54","author":"B Alc\u00e1zar-Navarrete","year":"2016","unstructured":"Alc\u00e1zar-Navarrete B, Romero-Palacios PJ, Ruiz-Sancho A, et al. Diagnostic performance of the measurement of nitric oxide in exhaled air in the diagnosis of COPD phenotypes. Nitric Oxide - Biology and Chemistry. 2016;54:67\u201372.","journal-title":"Nitric Oxide - Biology and Chemistry"},{"issue":"2","key":"1126_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2174\/1573398X13666170719154703","volume":"13","author":"A Corlateanu","year":"2017","unstructured":"Corlateanu A, Botnaru V, Rusu D, et al. Assessment of health-related quality of life in different phenotypes of COPD. Current Respiratory Medicine Reviews. 2017;13(2):105\u20139.","journal-title":"Current Respiratory Medicine Reviews"},{"issue":"9","key":"1126_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160770","volume":"11","author":"BG Cosio","year":"2016","unstructured":"Cosio BG, Soriano JB, L\u00f3pez-Campos JL, et al. Correction: distribution and outcomes of a phenotype-based approach to guide COPD management: results from the CHAIN cohort. PLoS One. 2016;11(9):e0160770.","journal-title":"PLoS One"},{"key":"1126_CR12","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2147\/COPD.S159834","volume":"13","author":"R Golpe","year":"2018","unstructured":"Golpe R, Su\u00e1rez-Valor M, Mart\u00edn-Robles I, et al. Mortality in COPD patients according to clinical phenotypes. Int J Chronic Obstructive Pulmonary Disease. 2018;13:1433\u20139.","journal-title":"Int J Chronic Obstructive Pulmonary Disease"},{"issue":"5","key":"1126_CR13","doi-asserted-by":"publisher","first-page":"1601446","DOI":"10.1183\/13993003.01446-2016","volume":"49","author":"V Koblizek","year":"2017","unstructured":"Koblizek V, Milenkovic B, Barczyk A, et al. Phenotypes of COPD patients with a smoking history in central and Eastern Europe: the POPE study. Eur Respir J. 2017;49(5):1601446.","journal-title":"Eur Respir J"},{"issue":"8","key":"1126_CR14","doi-asserted-by":"publisher","first-page":"992","DOI":"10.5588\/ijtld.15.0021","volume":"19","author":"M Miravitlles","year":"2015","unstructured":"Miravitlles M, Barrecheguren M, Rom\u00e1n-Rodr\u00edguez M. Frequency and characteristics of different clinical phenotypes of chronic obstructive pulmonary disease. Int J Tuberculosis Lung Disease. 2015;19(8):992\u20138.","journal-title":"Int J Tuberculosis Lung Disease"},{"key":"1126_CR15","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.2147\/COPD.S142997","volume":"12","author":"V Arkhipov","year":"2017","unstructured":"Arkhipov V, Arkhipova D, Miravitlles M, et al. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int J Chronic Obstructive Pulmonary Disease. 2017;12:3255\u201362.","journal-title":"Int J Chronic Obstructive Pulmonary Disease"},{"key":"1126_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2147\/COPD.S196109","volume":"14","author":"C-S Chai","year":"2019","unstructured":"Chai C-S, Liam C-K, Pang Y-K, et al. Clinical phenotypes of COPD and health-related quality of life: a cross-sectional study. Int J COPD. 2019;14:565\u201373.","journal-title":"Int J COPD"},{"key":"1126_CR17","unstructured":"Pan Qing,Lv Zhifang.clinical application value of the new guide patients with chronic obstructive pulmonary disease. J Shandong University (Health Sciences), 2016, 54(3): 63\u20137."},{"key":"1126_CR18","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.2147\/COPD.S137872","volume":"12","author":"M Calle Rubio","year":"2017","unstructured":"Calle Rubio M, Casamor R, Miravitlles M. Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD guidelines: the FENEPOC study. In tJ Chronic Obstructive Pulmonary Disease. 2017;12:2373\u201383.","journal-title":"In tJ Chronic Obstructive Pulmonary Disease"},{"issue":"4","key":"1126_CR19","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088\u2013101.","journal-title":"Biometrics"},{"issue":"20","key":"1126_CR20","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1002\/sim.2380","volume":"25","author":"RM Harbord","year":"2006","unstructured":"Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443\u201357.","journal-title":"Stat Med"},{"issue":"8","key":"1126_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1055\/s-0043-123846","volume":"143","author":"W Windisch","year":"2018","unstructured":"Windisch W. Cri\u00e9e CP.COPD-importance of lung function testing for diagnosis and treatment. Dtsch Med Wochenschr. 2018;143(8):593\u20136.","journal-title":"Dtsch Med Wochenschr"},{"key":"1126_CR22","unstructured":"Lei Zhu,Lijuan Hu,Li li,et al. Suggestions on diagnosis of pulmonary function. Chin J Tubere Respir Dis, 2018, 41(4): 308\u2013311."},{"key":"1126_CR23","doi-asserted-by":"crossref","unstructured":"Augustin IML,Wouters EFM,Houben-Wilke S,et al. Comprehensive Lung Function Assessment Does not Allow to Infer Response to Pulmonary Rehabilitation in Patients with COPD. J Clin Med, 2019, 8(1): pii: E27.","DOI":"10.3390\/jcm8010027"},{"key":"1126_CR24","unstructured":"GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. ; 2018 (https:\/\/goldcoped.org\/. Accessed 17 July 2018)."},{"issue":"1","key":"1126_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/atm.ATM_193_17","volume":"13","author":"U Hatipo\u011flu","year":"2018","unstructured":"Hatipo\u011flu U. Chronic obstructive pulmonary disease: more than meets the eye. Ann Thoracic Med. 2018;13(1):1\u20136.","journal-title":"Ann Thoracic Med"},{"issue":"6","key":"1126_CR26","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1093\/ije\/dyy221","volume":"47","author":"MC Magnus","year":"2018","unstructured":"Magnus MC, Henderson J, Tilling K, et al. Independent and combined associations of maternal and own smoking with adult lung function and COPD. Int J Epidemiol. 2018;47(6):1855\u201364.","journal-title":"Int J Epidemiol"},{"issue":"1 Pt 3","key":"1126_CR27","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jfma.2018.06.018","volume":"118","author":"SL Cheng","year":"2019","unstructured":"Cheng SL, Lin CH, Wang CC, et al. Comparison between COPD assessment test (CAT) and modified Medical Research Council (mMRC) dyspnea scores for evaluation of clinical symptoms, comorbidities and medical resources utilization in COPD patients. J Formos Med Assoc. 2019;118(1 Pt 3):429\u201335.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"1126_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/15412555.2019.1589443","volume":"16","author":"MR Grigsby","year":"2019","unstructured":"Grigsby MR, Siddharthan T, Pollard SL, et al. Low Body Mass Index Is Associated with Higher Odds of COPD and Lower Lung Function in Low- and Middle-Income Countries. Copd. 2019;16(1):58\u201365.","journal-title":"Copd"},{"key":"1126_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/COPD.S225156","volume":"15","author":"S Mansoor","year":"2020","unstructured":"Mansoor S, Obaida Z, Ballowe L, et al. Clinical impact of multidisciplinary outpatient care on outcomes of patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:33\u201342.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"671","key":"1126_CR30","first-page":"2082","volume":"15","author":"I Guerreiro","year":"2019","unstructured":"Guerreiro I, Soccal PM. COPD and phenotypes. Rev Med Suisse. 2019;15(671):2082\u20136.","journal-title":"Rev Med Suisse"},{"issue":"1","key":"1126_CR31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12911-019-0805-0","volume":"19","author":"M Pikoula","year":"2019","unstructured":"Pikoula M, Quint JK, Nissen F, et al. Identifying clinically important COPD sub-types using data-driven approaches in primary care population based electronic health records. BMC Med Inform Decis Mak. 2019;19(1):86.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"3\u20134","key":"1126_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/15412555.2019.1659760","volume":"16","author":"D Radovanovic","year":"2019","unstructured":"Radovanovic D, Contoli M, Marco FD, et al. Clinical and functional characteristics of COPD patients across GOLD classifications: results of a multicenter observational study. COPD. 2019;16(3\u20134):215\u201326.","journal-title":"COPD"},{"key":"1126_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2147\/COPD.S189384","volume":"14","author":"YS Jo","year":"2019","unstructured":"Jo YS, Kim SK, Park SJ, et al. Longitudinal change of FEV1 and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:361\u20139.","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-1126-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-020-1126-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-1126-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T19:12:50Z","timestamp":1619118770000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-020-1126-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1186\/s12890-020-1126-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.11323\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11323\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11323\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11323\/v4","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"16 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare second study are that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}